<div id="readability-page-1"><p>In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd, with a price target of <span id="expert-recommendation-target">A$0.60</span>.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Wakim covers the Healthcare sector, focusing on stocks such as CSL, Neuren Pharmaceuticals Limited, and Alcidion Group Limited. According to TipRanks, Wakim has an average return of <span>-5.3%</span> and a 41.82% success rate on recommended stocks. </p> <p>In addition to Bell Potter, Immutep Ltd also received a Buy from Canaccord Genuity’s Madeleine Williams in a report issued yesterday. However, on November 28, TR | OpenAI – 4o reiterated a Hold rating on Immutep Ltd (Other OTC: PRRUF).</p></div>

IMMP

<p>Bell Potter's Thomas Wakim maintains a Buy rating for Immutep Ltd with a price target of A$0.60. Despite Wakim's average return of -5.3% and a 41.82% success rate, Immutep also received a Buy rating from Canaccord Genuity's Madeleine Williams. However, TR | OpenAI reiterated a Hold rating on November 28.</p>

Bell Potter Sticks to Their Buy Rating for Immutep Ltd (PRRUF)